Drugmakers Drag Feet as Congress Drills Into Prescription Prices
From the article:
"'Pharmaceutical companies look at what happened to Martin Shkreli and Heather Bresch at Mylan and they don’t want their company to be the face of this year’s drug pricing scandal,' Rachel Sachs, a professor at Washington University in St. Louis who studies drug policy, said. She was referring to the two drug-industry executives who were brought before Congress in 2016 to answer for their companies’ pricing decisions.
The industry’s foot-dragging probably won’t stop lawmakers from acting on the issue, Sachs said."
Read more here!